151 related articles for article (PubMed ID: 38301967)
41. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Momeny M; Sankanian G; Hamzehlou S; Yousefi H; Esmaeili F; Alishahi Z; Karimi B; Zandi Z; Shamsaiegahkani S; Sabourinejad Z; Kashani B; Nasrollahzadeh A; Mousavipak SH; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2020 Sep; 882():173298. PubMed ID: 32593665
[TBL] [Abstract][Full Text] [Related]
42. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
43. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
44. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.
Jin D; Guo J; Wang D; Wu Y; Wang X; Gao Y; Shao C; Xu X; Tan S
EBioMedicine; 2018 Nov; 37():188-204. PubMed ID: 30389502
[TBL] [Abstract][Full Text] [Related]
45. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
46. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
47. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
48. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
49. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.
Luo M; Wang F; Zhang H; To KKW; Wu S; Chen Z; Liang S; Fu L
Signal Transduct Target Ther; 2020 Aug; 5(1):141. PubMed ID: 32855386
[TBL] [Abstract][Full Text] [Related]
50. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
51. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
52. Interferon-gamma signaling in human retinal pigment epithelial cells mediated by STAT1, ICSBP, and IRF-1 transcription factors.
Li W; Nagineni CN; Hooks JJ; Chepelinsky AB; Egwuagu CE
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):976-82. PubMed ID: 10102295
[TBL] [Abstract][Full Text] [Related]
53. Metastatic melanoma cells evade immune detection by silencing STAT1.
Osborn JL; Greer SF
Int J Mol Sci; 2015 Feb; 16(2):4343-61. PubMed ID: 25690042
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
55. Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells.
Zhang L; Cheng T; Yang H; Chen J; Wen X; Jiang Z; Yi H; Luo Y
Med Oncol; 2022 Jan; 39(4):38. PubMed ID: 35092496
[TBL] [Abstract][Full Text] [Related]
56. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
[TBL] [Abstract][Full Text] [Related]
57. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Cui X; Dong K; Guo Y; Geller DA
Br J Cancer; 2021 Jul; 125(1):101-111. PubMed ID: 33772151
[TBL] [Abstract][Full Text] [Related]
58. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
59. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
60. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]